A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT03071757. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT03071757
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 139 participants
Conditions and interventions
Conditions
Interventions
- ABBV-181 Drug
- ABBV-368 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 20, 2017
- Primary completion
- Apr 12, 2022
- Completion
- Apr 12, 2022
- Last update posted
- Apr 27, 2022
2017 – 2022
United States locations
- U.S. sites
- 10
- U.S. states
- 6
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Moores Cancer Center at UC San Diego /ID# 201334 | La Jolla | California | 92093 | — |
| University of California, Davis Comprehensive Cancer Center /ID# 201342 | Sacramento | California | 95817 | — |
| Stanford University /ID# 206949 | Stanford | California | 94305 | — |
| Yale University /ID# 207895 | New Haven | Connecticut | 06510 | — |
| Carolina BioOncology Institute /ID# 160786 | Huntersville | North Carolina | 28078 | — |
| Greenville Hospital System /ID# 160785 | Greenville | South Carolina | 29605 | — |
| University of Texas Southwestern Medical Center /ID# 201934 | Dallas | Texas | 75390-7208 | — |
| South Texas Accelerated Research Therapeutics /ID# 160788 | San Antonio | Texas | 78229 | — |
| University of Virginia /ID# 212895 | Charlottesville | Virginia | 22908 | — |
| Virginia Cancer Specialists - Fairfax /ID# 160787 | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03071757, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 27, 2022 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03071757 live on ClinicalTrials.gov.